Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shangpharma Innovation Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, indicating separate examination contexts for the current docket.
KIM, SEONG JONG is the busiest examiner, with 1 pending matter. Since that is below the portfolio total, the examiner handles only one part of the docket. Counsel should prepare matter-specific responses and avoid assuming that the treatment in one art unit will apply to the other.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 1 | 20.0% | +0.0% |
| ANDERSON, REBECCA L | 1 | 73.5% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578875 | SMALL MOLECULES INHIBITORS OF CYCLIC GMP-AMP SYNTHASE (cGAS) | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17777832 | CASPASE 6 INHIBITORS AND USES THEREOF | ANDERSON, REBECCA L | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578875 | SMALL MOLECULES INHIBITORS OF CYCLIC GMP-AMP SYNTHASE (cGAS) | KIM, SEONG JONG | 1621 | §102§103 | Final Rejection | — | Pending | Jan 12, 2024 |
| 17777832 | CASPASE 6 INHIBITORS AND USES THEREOF | ANDERSON, REBECCA L | 1626 | §102 | Non-Final OA | 30d overdue | Pending | May 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShangpharma Innovation Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Seong Jong Kim has the most, with 1 of Shangpharma Innovation Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.